NOVEL AGENTS FOR THE TREATMENT OF HEART FAILURE
PDF

Як цитувати

Parchami , G. S., & Hameed , M. (2021). NOVEL AGENTS FOR THE TREATMENT OF HEART FAILURE. ГРААЛЬ НАУКИ, (5), 364-365. https://doi.org/10.36074/grail-of-science.04.06.2021.075
https://doi.org/10.36074/grail-of-science.04.06.2021.075
PDF

Посилання

Berliner, D., & Bauersachs, J. (2019). New drugs: big changes in conservative heart failure therapy?. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 55(Suppl 1), i3–i10. https://doi.org/10.1093/ejcts/ezy421.

Li, H., Duan, Y., Chen, B., Zhao, Y., Su, W., Wang, S., … Lu, L. (2020). New pharmacological treatments for heart failure with reduced ejection fraction (HFrEF): A Bayesian network meta-analysis. Medicine, 99(5), e18341. https://doi.org/10.1097/MD.0000000000018341.

Machaj, F., Dembowska, E., Rosik, J., Szostak, B., Mazurek-Mochol, M., & Pawlik, A. (2019). New therapies for the treatment of heart failure: a summary of recent accomplishments. Therapeutics and clinical risk management, 15, 147–155. https://doi.org/10.2147/TCRM.S179302.

4-Metra, M., Teerlink, J. R., Cotter, G., Davison, B. A., Felker, G. M., Filippatos, G., …Crespo-Leiro, M. G. RELAX-AHF-2 Committees Investigators (2019). Effects of Serelaxin in Patients with Acute Heart Failure. The New England journal of medicine, 381(8), 716–726. https://doi.org/10.1056/NEJMoa1801291.

Papp, Z., Agostoni, P., Alvarez, J., Bettex, D., Bouchez, S., Brito, D., … Pollesello, P. (2020). Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. Cardiac failure review, 6, e19. https://doi.org/10.15420/cfr.2020.03.

Savarese, G., & Lund, L. H. (2017). Global Public Health Burden of Heart Failure. Cardiac failure review, 3(1), 7–11. https://doi.org/10.15420/cfr.2016:25:2

Creative Commons License

Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.


| Переглядів: 13 | Завантажень: 19 |